Tirzepatide (LY3298176) is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist with potential use in type 2 diabetes research.
| Molecular Weight | 4813.45 |
| Formula | C225H348N48O68 |
| CAS Number | 2023788-19-2 |
| Solubility (25°C) | DMSO 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Yahiya Y Syed. Drugs. Tirzepatide: First Approval
[2] Ania M Jastreboff, et al. N Engl J Med. Tirzepatide Once Weekly for the Treatment of Obesity
| Related GLP Receptor Products |
|---|
| Amycretin
Amycretin is a novel, potentially first-in-class, long-acting co-agonist of GLP-1 and the amyloid receptor (AMYR) for obesity-related studies. |
| NM-003
NM-003 is a GLP-2R agonist that can be used in studies related to inflammatory bowel disease. |
| NB-1002
NB-1002 is a GLP-2R agonist that can be used in studies related to short bowel syndrome. |
| MOD-15014
MOD-15014 is a GLP-2R modulator that can be used in studies related to short bowel syndrome. |
| HM-15912
HM-15912 is a GLP-2R agonist that can be used in studies related to short bowel syndrome. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
